Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Zacks07-04

Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy for the initial treatment of locally advanced ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448248624?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d","is_english":true,"pubTime":"2024-07-04 21:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2448248624","market":"us","top_or_hot":-1,"title":"Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals","media":"Zacks","content":"<div>\n<p>Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy for the initial treatment of locally advanced ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roches-rhhby-combo-therapy-misses-132500528.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roches-rhhby-combo-therapy-misses-132500528.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy for the initial treatment of locally advanced ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roches-rhhby-combo-therapy-misses-132500528.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://finance.yahoo.com/news/roches-rhhby-combo-therapy-misses-132500528.html","article_id":"2448248624","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448248624","pubTimestamp":1720099500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"RocheRHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq  and chemotherapy for the initial treatment of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer patients failed to achieve its primary goals. Initial or first-line treatment refers to those patients who have previously not been treated for this indication.The phase II/III SKYSCRAPER-06 study evaluated Roche’s combination therapy compared with Merck’s MRK Keytruda  and chemotherapy in 542 patients with the lung cancer indication. The study's primary endpoints comprised progression-free survival  and overall survival .Roche’s tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. The candidate’s unique mechanism of action suppresses the immune response to cancer and acts as an immune amplifier when combined with othercancer immunotherapies, such as Tecentriq.Merck’s Keytruda is currently marketed as the s","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","CGEN":"Compugen医疗","BK4225":"医疗保健房地产信托","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4516":"特朗普概念","BK4534":"瑞士信贷持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","HR":"医疗保健房地产信托","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4211":"区域性银行","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4007":"制药","SG9999014542.SGD":"United Income Focus Trust Acc SGD","MRK":"默沙东","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","03165":"华夏欧优股对冲","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","PFS":"Provident Financial Services Inc","BK4559":"巴菲特持仓","BK4121":"生命科学工具和服务","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","ALXO":"ALX Oncology Holdings","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0058720904.USD":"联博国际健康护理基金A","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","RHHBY":"罗氏控股"},"translate_title":"罗氏(RHHBY)组合疗法未能实现肺癌研究目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HR":1,"CGEN":1,"MRK":1,"PFS":1,"RHHBY":1,"ALXO":0.9,"03165":0.6},"content_text":"Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy for the initial treatment of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer patients failed to achieve its primary goals. Initial or first-line treatment refers to those patients who have previously not been treated for this indication. \nThe phase II/III SKYSCRAPER-06 study evaluated Roche’s combination therapy compared with Merck’s MRK Keytruda (pembrolizumab) and chemotherapy in 542 patients with the lung cancer indication. The study's primary endpoints comprised progression-free survival (PFS) and overall survival (OS).\nRoche’s tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. The candidate’s unique mechanism of action suppresses the immune response to cancer and acts as an immune amplifier when combined with othercancer immunotherapies, such as Tecentriq.\nThe study results showed that the combination of tiragolumab plus Tecentriq and chemotherapy was less effective in PFS and OS compared with the control group (Keytruda + chemotherapy). At the time of primary analysis, the PFS had a hazard ratio (HR) of 1.27, while the OS at its first interim analysis had an HR of 1.33, which was immature. Both data indicate reduced efficacy compared to treatment with Merck’s Keytruda and chemotherapy in the treated patient population, which includes the phase II and phase III cohorts.\nAs a result, Roche intends to halt the phase II/III SKYSCRAPER-06 study and patients and investigators will be unblinded. The findings will be shared with health authorities and presented at a future medical meeting.\nThe safety profile of the combination therapy of tiragolumab plus Tecentriq and chemotherapy was consistent with previous findings, with no new or unexpected issues.\nRoche further clarified that ongoing phase III studies of its combination therapy are exploring treatment settings and indications different than those in the SKYSCRAPER-06 study.\nYear to date, shares of RHHBY have lost 5.9% against the industry’s 21.1% growth.\nImage Source: Zacks Investment Research\nRoche’s blockbuster immuno-oncology drug, Tecentriq, is currently approved in the United States, EU and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer.\nThe drug also makes a significant contribution to the company’s top line. In the first quarter of 2024, Tecentriq recorded sales worth CHF 865 million, which represents year-over-year growth of 1%.\nRoche’s extensive development program for Tecentriq includes multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.\nMerck’s Keytruda is currently marketed as the standard of care in the frontline treatment of metastatic non-small cell lung cancer patients. Keytruda, an anti-PD-1 therapy, is MRK’s blockbuster oncology drug. It is approved for several types of cancer, accounting alone for 47% of the company’s pharmaceutical sales in 2023.\nKeytruda is continuously growing and expanding into new indications and markets globally, bolstering Merck’s position in the oncology market. Merck’s Keytruda is presently approved to treat eight indications in earlier-stage cancers in the United States.\nZacks Rank and Stocks to Consider\nRoche currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the drug/biotech industryworth mentioning are ALX Oncology Holdings ALXO and Compugen CGEN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has remained constant at $2.89. During the same period, the consensus estimate for 2025 loss per share has remained constant at $2.73. Year to date, shares of ALXO have plunged 62.4%.\nALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.\nIn the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has remained constant at 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have lost 15.7%.\nCGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nCompugen Ltd. (CGEN) : Free Stock Analysis Report\nALX Oncology Holdings Inc. (ALXO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448248624"}